BTIG raised the firm’s price target on Ideaya Biosciences to $62 from $55 and keeps a Buy rating on the shares after the company presented data from the Phase 2 expansion study of IDE397 as a monotherapy including an “impressive” 39% overall response rate, or ORR, and positive initial signs of durability with clean safety. Following the data, the firm increased its view of the odds of success for IDE397 in non-small cell lung cancer, or NSCLC, and bladder cancer, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- IDEAYA Biosciences Announces Chief Legal Officer’s Resignation
- Ideaya announces first-patient-in for Phase 1 trial of IDE397 with Trodelvy
- Ideaya Biosciences announces clinical program updates for IDE397
- Ideaya Biosciences price target raised to $63 from $55 at Stifel
- Ideaya Biosciences announces results from darovasertib trial